Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma

Viruses

Koji Kato¹  Koichi Akashi² 

[1] Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan

关键词: adult T-cell leukemia/lymphoma;    allogeneic hematopoietic stem cell transplantation;    graft-versus-host disease;    mogamulizumab;    chemotherapy;    antiviral therapy;   

DOI  :  10.3390/v7122960

来源: mdpi

【 摘 要 】

Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia/lymphoma virus type 1 (HTLV-1). ATLL occurs in approximately 3%–5% of HTLV-1 carriers during their lifetime and follows a heterogeneous clinical course. The Shimoyama classification has been frequently used for treatment decisions in ATLL patients, and antiviral therapy has been reportedly promising, particularly in patients with indolent type ATLL; however, the prognosis continues to be dismal for patients with aggressive-type ATLL. Recent efforts to improve treatment outcomes have been focused on the development of prognostic stratification and improved dosage, timing, and combination of therapeutic modalities, such as antiviral therapy, chemotherapy, allogeneic hematopoietic stem cell transplantation, and molecular targeted therapy.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.